chufangao/CTO huggingface dataset:
Clinical trial NCT03622593: A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
Official title: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)
Acronym: RHINE
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 951.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-10-09
Primary completion date: 2020-10-19
Completion date: 2023-05-31
Baseline population: The overall number of baseline participants (951) comprises the Intent-to-Treat (ITT) Population, which includes all global participants who were randomized in the study, grouped according to the treatment assigned at randomization.
Limitations and caveats: All secondary outcome measures were unpowered for statistical analysis, and the results should be interpreted with caution.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).~For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT02021526: Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)
Official title: Treatment Development of Triheptanoin for Glucose Transporter Type I Deficiency
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: NIH funding resulted in new clinical trial
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-31
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Clinical trial NCT03037736: Outpatient Performed Pterygium Surgery Study
Official title: Outpatient Performed Pterygium Surgery Study
Acronym: OPPS
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Funding not received.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-03-01
Primary completion date: 2020-03-01
Completion date: 2020-03-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05177029: Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants
Official title: Interventional, Randomized, Double-Blind, Sequential-Part, Placebo-Controlled, Single- and Multiple-Dose Study Investigating Safety, Tolerability, and Pharmacokinetic Properties of Lu AG06466 in Healthy Young Japanese and Caucasian Subjects
Sponsor: H. Lundbeck A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated for strategic reasons.
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-26
Primary completion date: 2021-12-29
Completion date: 2021-12-29
Clinical trial NCT04364035: Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients
Official title: A Phase IIa Randomised, Double-blind, Placebo-controlled Study of HIV-1 Vaccines MVA.HTI and ChAdOx1.HTI With TLR7 Agonist Vesatolimod (GS-9620) in Early Treated HIV-1 Infection
Acronym: AELIX-003
Sponsor: Aelix Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-20
Primary completion date: 2022-10-03
Completion date: 2022-12-16
Clinical trial NCT04451720: Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
Official title: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult Japanese Subjects With Moderate to Severe Palmoplantar Pustulosis
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 119.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-20
Primary completion date: 2022-11-21
Completion date: 2022-11-21
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT02697617: Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
Official title: Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney
Acronym: PIOPKD
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-01-26
Primary completion date: 2019-10-31
Completion date: 2020-01-31
Baseline population: 18 patients randomized to either pioglitazone for 12 months and then placebo for 12 months and then cross over to the other arm. So baseline data represents both arms
Limitations and caveats: The major limitation is the small sample size.
Plan to share individual participant data: NO
Clinical trial NCT04507438: The Effect of Donepezil on Glycemic Control in Type II Diabetics
Official title: The Effect of Donepezil on Glycemic Control in Type II Diabetics
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of enrollment
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-12
Primary completion date: 2023-09-12
Completion date: 2023-09-12
Clinical trial NCT02727998: Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy
Official title: Combining Neurobiology and New Learning: Ketamine and Prolonged Exposure: A Potential Rapid Treatment for Post Traumatic Stress Disorder (PTSD)
Acronym: PTSD
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study ran out of funding
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-31
Primary completion date: 2021-11-28
Completion date: 2021-11-28
Limitations and caveats: Due to study termination, full enrollment was not achieved and therefore the intended regression modeling was not performed.
Plan to share individual participant data: NO
IPD sharing description: Data from the initial stage of the investigation will be used to establish support for a Phase 3 RCT.
Clinical trial NCT01436656: A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Official title: A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LGX818 in Adult Patients With Locally Advanced or Metastatic BRAF Mutant Melanoma
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 93.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-09-05
Primary completion date: 2012-10-01
Completion date: 2022-11-07
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03672643: Long Term Safety Observation of Crizotinib in Chinese NSCLC Population
Official title: AN OPEN-LABEL, SINGLE-ARM STUDY OF THE LONG-TERM SAFETY OF XALKORI (REGISTERED) IN PATIENTS FROM CHINA WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) OR ROS1 LOCUS WHO HAVE PREVIOUSLY BEEN TREATED ON A STUDY OF XALKORI (REGISTERED)
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The trial is terminated based on business decision, not due to safety concerns or regulatory requirements.
Enrollment: 41.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-28
Primary completion date: 2023-09-28
Completion date: 2023-09-28
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04879823: Post-operative Course of Dexamethasone to Reduce Tonsillectomy Morbidity
Official title: Post-operative Course of Dexamethasone to Reduce Tonsillectomy Morbidity
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: slow recruitment
Enrollment: 222.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-05
Primary completion date: 2023-07-11
Completion date: 2023-07-11
Baseline population: Excludes patients withdrawn due to protocol violation and physician decision
Limitations and caveats: Early termination due to slow recruitment in older cohorts (8-12 and 13-17-year-olds) leading to small numbers of subjects analyzed in those age groups.
Plan to share individual participant data: NO
IPD sharing description: Only co-investigators as listed under the University of Pittsburgh IRB (Institutional Review Board) protocol for this study will have access to all data and analysis. Data will be shared via UPMC-associated OneDrive and will only be shared between these investigators.
Clinical trial NCT03266991: Treatment of Latent Tuberculosis in Socially Marginalised Citizens
Official title: A Randomised Controlled Trial of a 12-dose Rifapentine and Isoniazid (RPT+INH) Regimen Using Direct Observed Therapy (DOT) Versus 6 Months of Daily Isoniazid for Latent Tuberculosis Infection (LTBI) in Socially Marginalised People
Acronym: DOT-LTBI
Sponsor: Aarhus University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Recruitment issues
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-27
Primary completion date: 2023-02-09
Completion date: 2023-02-09
Plan to share individual participant data: NO
Clinical trial NCT03018288: Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Official title: A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study closed early due to poor accrual.
Enrollment: 90.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-09-21
Primary completion date: 2022-12-20
Completion date: 2022-12-20
Plan to share individual participant data: YES
IPD sharing description: All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP). All collected IPD will be shared with collaborators under the terms of collaborative agreements.
IPD time frame: Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol Genomic Data Sharing (GDS) plan for as long as database is active. All collected individual participant data (IPD) will be available after primary analysis has been published.
IPD access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Genomic data are made available via the database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.
Clinical trial NCT04382898: PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
Official title: First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer
Acronym: PRO-MERIT
Sponsor: BioNTech SE (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 75.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-12-19
Primary completion date: 2024-01-23
Completion date: 2024-01-23
Plan to share individual participant data: NO
Clinical trial NCT04065087: Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma
Official title: A Phase 1/2, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability, Anti-tumor Activity of GX-I7 Plus Adjuvant Temozolomide Combination Regimen in Patients With Newly Diagnosed With Glioblastoma
Sponsor: Genexine, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Canceled by the sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-22
Primary completion date: 2022-05-27
Completion date: 2022-08-27
Plan to share individual participant data: NO
Clinical trial NCT03056495: Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease
Official title: Multicenter, Open-label Phase Ib Dose-escalation and Dose-confirmational Study for the Tolerability and Safety of N-hydroxy-N'-Phenyl-octanediamide (Vorinostat) in Patients With Mild Alzheimer's Disease
Acronym: VostatAD01
Sponsor: German Center for Neurodegenerative Diseases (DZNE) (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Insufficient Recruitment
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-09-28
Primary completion date: 2024-03-04
Completion date: 2024-03-04
Plan to share individual participant data: NO
Clinical trial NCT02709993: Consolidation Therapy in Patients With Hematologic Malignancies
Official title: Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose GM-CSF, As Consolidation Treatment in Patients With Hematologic Malignancies
Sponsor: Kiromic BioPharma Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Study unable to enroll patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-28
Primary completion date: 2020-10-31
Completion date: 2020-10-31
Clinical trial NCT02902055: Paediatric Ards Neuromuscular Blockade Study
Official title: Life-threatening Acute Respiratory Failure in Children: to Breathe or Not to Breathe Spontaneously, That's the Question
Acronym: PAN
Sponsor: University Medical Center Groningen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Why stopped: COVID
Enrollment: 178.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2019-12-01
Primary completion date: 2024-05-01
Completion date: 2024-05-01
Plan to share individual participant data: YES
Clinical trial NCT03322215: HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
Official title: A Phase 2, International, Multicenter, Open-labeled, Randomized Trial of PAlbociclib and Fulvestrant vs. Standard Oral Capecitabine In Patients With Hormone Receptor (HR)+ / HER2- Advanced Breast Cancer and Documented Endocrine Resistance
Acronym: PASIPHAE
Sponsor: Karolinska University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 42.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-24
Primary completion date: 2021-04-30
Completion date: 2023-10-31
Clinical trial NCT02579265: Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants
Official title: A Prospective, Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants Requiring 28 Days of Parenteral Nutrition
Sponsor: Fresenius Kabi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Outcome of a planned interim analysis was that the sample size required to show superiority was too high to be feasible. Fresenius Kabi requested termination to the FDA on 17 Jan 2020. FDA accepted termination by written response on 16 Apr 2020.
Enrollment: 204.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-31
Primary completion date: 2020-04-03
Completion date: 2020-04-10
Clinical trial NCT03862079: Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics
Official title: Randomized Phase II Trial of Total Gut Decontamination Followed by Fecal Microbiota Transplant (FMT), FMT-Alone or Standard of Care for Reduction in Acute Graft-Versus-Host Disease of the Gastrointestinal Tract in Patients Given Broad-Spectrum Antibiotics
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Per PI's request
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-06-01
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Clinical trial NCT03552575: The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Official title: The Effects of Sacubitril/Valsartan Compared to Valsartan on Left Ventricular Remodelling in Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction: a Randomised, Double-blinded, Active-comparator, Cardiac-MR Based Trial
Acronym: RECOVER-LV
Sponsor: NHS Greater Glasgow and Clyde (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 93.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-01
Primary completion date: 2020-07-25
Completion date: 2020-07-25
Plan to share individual participant data: NO
Clinical trial NCT04407442: Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
Official title: Phase II Study of Daratumumab in Combination With Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated With Daratumumab
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow enrollment and change in sponsor direction
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-30
Primary completion date: 2023-04-30
Completion date: 2023-04-30
Limitations and caveats: The study was closed to enrollment earlier than expected due to slow enrollment and change in sponsor research direction.
Plan to share individual participant data: NO
Clinical trial NCT04783389: A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate CBP-201 in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps
Sponsor: Suzhou Connect Biopharmaceuticals, Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Trial was discontinued in 2022 due to COVID-19 pandemic and Ukraine/Russia conflict related enrollment challenges. Discontinuation was not related to safety.
Enrollment: 40.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-06-16
Primary completion date: 2022-04-15
Completion date: 2022-06-10
Limitations and caveats: The study was prematurely discontinued after 40 patients were enrolled due to recruitment issues resulting from the COVID-19 pandemic and operational issues such as the inability to fully conduct/implement the study (e.g., monitoring, logistics of drug supply, transportation of clinical testing samples, etc.) due to the Russian invasion of Ukraine in Mar 2022.~Because only limited data was collected, no definitive conclusions can be made at the pre-planned 24-week primary endpoint.
Plan to share individual participant data: NO
Clinical trial NCT04675086: Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection
Official title: A Randomized, Open-Label Study of the Efficacy and Safety of Aralast NP, an Alpha-1 Antitrypsin Infusion Therapy With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection
Sponsor: Blessing Corporate Services, Inc (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Administrative Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-31
Primary completion date: 2021-09-30
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT03574649: QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
Official title: QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
Sponsor: ImmunityBio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Trial not initiated
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-30
Primary completion date: 2019-12-30
Completion date: 2020-12-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02169089: Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial
Official title: Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial
Sponsor: University Hospitals Cleveland Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 79.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-01-31
Primary completion date: 2022-04-29
Completion date: 2022-04-29
Clinical trial NCT04349124: Persistent Postpartum Hypertension Pilot Trial
Official title: Pilot Treatment of Persistent Non-Severe Postpartum Hypertension
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Unable to continue recruiting
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-25
Primary completion date: 2021-02-12
Completion date: 2021-03-04
Baseline population: Participants who completed the study.
Plan to share individual participant data: NO